Breast cancer stem cells, commonly called CSCs, represent a relatively small and adaptable population within a tumor. Unlike most rapidly dividing cancer cells, CSCs can self-renew, generate more differentiated tumor cells, and survive conditions that eliminate other malignant cells. These properties have been linked to recurrence, metastasis, and treatment failure. Although cancer metabolism has often been associated with increased glucose consumption and glycolysis, CSCs can also depend heavily on mitochondria, the organelles that generate ATP through oxidative phosphorylation. This reliance led the researchers to investigate POLG, the enzyme responsible for copying and repairing mitochondrial DNA.

POLG operates as a two-part molecular machine. The catalytic subunit is encoded by the POLG1 gene, while the accessory subunit is encoded by POLG2. Together, these proteins help replicate the small circular genome carried inside mitochondria. Mitochondrial DNA encodes essential components of the respiratory chain, the series of protein complexes that transfer electrons and use the released energy to produce ATP. If mitochondrial DNA is depleted or damaged, respiratory-chain assembly can fail, reducing energy production and altering the balance of reactive oxygen species inside the cell. The researchers therefore asked whether impairing POLG would interfere with the biology of breast cancer stem cells.

The experiments were initially performed in MCF-7 cells, an estrogen receptor-positive breast cancer model. Using genetic silencing, the investigators reduced expression of either POLG1 or POLG2. The effects on mitochondrial DNA were substantial: POLG1 silencing lowered mitochondrial DNA content by about 80%, while POLG2 silencing caused an approximately 70% reduction. These changes were accompanied by decreased levels of MTCO2, a protein encoded by mitochondrial DNA and required for respiratory-chain function. Measurements of mitochondrial membrane potential, respiration, and ATP production also indicated that the organelles were operating less efficiently after POLG disruption.

The mitochondrial defects were closely associated with a loss of stemness-related characteristics. In MCF-7 cells, silencing POLG1 reduced expression of OCT4, a transcription factor involved in maintaining cellular plasticity and self-renewal. The cells also formed roughly 70% fewer mammospheres, three-dimensional structures used as an in vitro indicator of mammary stem-cell activity. Their ability to generate colonies was markedly suppressed as well. Silencing POLG2 produced a similar pattern, reducing OCT4 expression, mammosphere formation, and clonogenic growth. Notably, these interventions did not substantially affect short-term growth in conventional two-dimensional cultures, suggesting that mitochondrial POLG activity may be particularly important for long-term self-renewal rather than immediate cell proliferation.

The study also examined how POLG disruption changed the chemical environment within mitochondria. Loss of mitochondrial membrane potential is a sign that the electrochemical gradient used to drive ATP synthesis has been weakened. At the same time, POLG1 and POLG2 silencing increased mitochondrial superoxide, a reactive oxygen species generated when electrons leak from the respiratory chain. This increase did not translate into a statistically significant rise in total cellular reactive oxygen species in every experiment, indicating that mitochondrial stress and whole-cell oxidative stress are not identical measurements. The results instead point to a localized disturbance in mitochondrial redox balance that may contribute to the loss of CSC-associated properties.

To test whether the genetic results could be reproduced with drugs, the researchers examined Alovudine, a nucleoside reverse transcriptase inhibitor developed for antiviral use. Alovudine can inhibit POLG as an off-target effect, although it is not a selective POLG-directed cancer drug. In the breast cancer cells, the compound reduced mammosphere and colony formation while lowering MTCO2 expression, mitochondrial respiration, and ATP generation. The authors emphasize that Alovudine caused hematological toxicities during antiviral development, making it unsuitable as an established cancer treatment on the basis of these experiments. Its role in the study was primarily to provide pharmacological support for the idea that POLG-dependent mitochondrial function is connected to cancer stemness.

The investigators then used a second compound, zalcitabine, also known as ddC, to determine whether the observations depended on a single drug. In MCF-7 cells, ddC impaired mitochondrial respiration, reduced MTCO2 levels, and suppressed both mammosphere and colony formation. The researchers extended the analysis to T47D, MDA-MB-231, MDA-MB-436, and MDA-MB-453 breast cancer cells, representing different biological subtypes and molecular characteristics. Across these models, ddC consistently reduced mammosphere formation, although its effects on ordinary monolayer growth varied. Non-tumoral MCF10A mammary epithelial cells showed limited viability changes under the tested conditions, a result that may indicate some degree of selectivity but cannot substitute for formal toxicity and therapeutic-index studies.

The molecular response to ddC also varied between cancer models. In MCF-7 cells, the compound markedly reduced the stemness-associated transcription factors SOX2 and NANOG. In MDA-MB-453 cells, SOX2 declined, whereas the effect on NANOG was more modest. Such differences are important because breast cancer is not a single disease: tumors differ in receptor status, genomic alterations, mitochondrial activity, and dependence on particular metabolic pathways. The researchers additionally analyzed clinical data from 458 patients with high-risk, estrogen receptor-positive, lymph node-positive luminal A breast cancer. Higher POLG1 expression was associated with poorer overall survival, with a hazard ratio of 1.34, and with shorter relapse-free, distant metastasis-free, and post-progression survival. These preliminary associations do not prove that POLG drives poor outcomes, and they require validation in independent patient cohorts using multivariable analyses.

The authors describe the work as a pilot study and stress that important questions remain unanswered. Much of the genetic evidence came from MCF-7 cells, and shRNA-based experiments can produce off-target effects that complicate interpretation. Neither Alovudine nor ddC is a fully selective POLG inhibitor, so their effects may involve additional molecular targets. The experiments were performed in cultured cells rather than animals or patients, meaning that the study does not yet demonstrate tumor suppression in a living organism or establish whether POLG inhibition can spare normal tissues. Future research will need to use independent genetic strategies, selective chemical probes, patient-derived models, xenografts, and orthotopic tumors. Nevertheless, the study identifies a compelling connection between mitochondrial DNA maintenance and breast cancer stem-cell behavior. By showing that POLG disruption can weaken mitochondrial respiration, alter redox balance, and suppress self-renewal across multiple models, the findings position POLG as a candidate biomarker and a possible target for therapies designed to attack the metabolically resilient cells that help breast tumors persist and return.

Subject of Research: Cells

Article Title: Investigating POLG-driven modulation of cancer stemness: a pilot study in breast cancer cells

News Publication Date: 24 August 2026

Web References: Aging, Volume 18; https://doi.org/10.18632/aging.206406; Aging-US

References: Chinigò et al., “Investigating POLG-driven modulation of cancer stemness: a pilot study in breast cancer cells,” Aging, DOI: 10.18632/aging.206406

Image Credits: Copyright © 2026 Chinigò et al.; Figure 2, distributed under the Creative Commons Attribution License (CC BY 4.0).

Keywords: breast cancer, cancer stem cells, cancer metabolism, POLG, POLG1, POLG2, mitochondrial DNA, mitochondrial function, oxidative phosphorylation, cancer stemness

Mitochondria, often described as the cellular powerhouses, are central to energy production via oxidative phosphorylation. Within this process, the electron transport chain (ETC) orchestrates a complex series of redox reactions across four major complexes embedded in the inner mitochondrial membrane. Complex III, known scientifically as the cytochrome bc1 complex, serves as a critical conduit facilitating electron transfer from ubiquinol to cytochrome c. The precise regulation of this complex is essential not only for adenosine triphosphate (ATP) production but also for maintaining cellular redox homeostasis. The novel approach explored in this study meticulously targets this complex, manipulating electron flux to enhance ROS generation, which, in turn, exerts selective cytotoxic effects on malignant cells.

Reactive oxygen species, traditionally perceived as harmful metabolic byproducts, have increasingly been recognized for their dualistic role in cellular physiology. While excessive ROS can induce oxidative stress and damage, controlled elevation of ROS within cancer cells can overwhelm antioxidant defenses, triggering apoptosis and necrosis. The study highlights how strategic modulation of electron transfer kinetics at respiratory complex III can amplify superoxide production, tipping the balance toward lethal oxidative stress exclusive to tumor cells. This targeted ROS induction distinguishes itself from conventional chemotherapeutics by minimizing collateral damage to healthy tissues.

Cancer cells notoriously reprogram their metabolism, adapting their mitochondrial function to support rapid proliferation and survival under hypoxic conditions. This metabolic plasticity often confers resistance to therapies aimed at conventional targets. By focusing on the subtle electron transfer events within complex III, the researchers harness an underexplored vulnerability inherent to mitochondrial bioenergetics. The disruption of electron flow not only induces ROS-mediated damage but also impairs ATP synthesis, exacerbating metabolic stress and promoting cell death. This dual assault is a critical advantage over monolithic therapeutic strategies.

Central to the therapeutic implications is the precise engineering of molecules or interventions that can modulate electron transfer without causing systemic mitochondrial dysfunction. The authors employ sophisticated biochemical assays and high-resolution spectroscopic techniques to elucidate the interaction dynamics at the Qo and Qi sites of complex III. This mechanistic insight lays the groundwork for designing selective inhibitors or enhancers that can transiently perturb electron flow, unleashing ROS bursts within targeted cancerous mitochondria. Such precision is paramount to avoiding unintended side effects in non-malignant cells dependent on mitochondrial respiration.

An intriguing aspect of the study is the exploration of differential ROS thresholds between cancer and normal cells. Cancer cells, due to their elevated basal oxidative stress and compromised antioxidant capacity, are more susceptible to additional ROS insults. This vulnerability is exploited by increasing electron leakage at complex III, effectively saturating the redox buffering systems in malignant cells. The research delineates how this selective ROS-mediated cytotoxicity spares healthy cells, bolstering the potential safety profile of therapies designed around this mechanism.

The researchers also investigate the interplay between modulated electron transfer and downstream signaling cascades known to regulate cell fate. Elevated ROS levels trigger oxidative modifications in key signaling proteins, activating pathways that culminate in mitochondrial permeability transition pore opening, release of pro-apoptotic factors, and activation of caspases. This integrated response underscores the complexity and effectiveness of targeting mitochondrial electron transport to induce programmed cell death, providing a multi-faceted attack on cancer cell viability.

Beyond monotherapy potential, the study contemplates synergistic applications with existing treatments. The enhanced ROS production via manipulated complex III activity could sensitize tumor cells to radiation and chemotherapeutic agents known to further exacerbate oxidative stress. Combination regimens leveraging this mechanism may reduce required dosages and associated toxicities while overcoming resistance mediated by traditional antioxidant upregulation in tumors. This line of inquiry opens avenues for integrative cancer therapies rooted in mitochondrial bioenergetic manipulation.

Importantly, the study also addresses the heterogeneity among cancer types, recognizing that metabolic phenotypes vary widely across tumors. Through comparative analyses of different cancer cell lines, the researchers identify responsiveness patterns correlated with mitochondrial respiratory profiles. This stratification approach advocates for personalized medicine paradigms where patients with tumors exhibiting certain mitochondrial dynamics could benefit most from complex III-targeted ROS modulation, enhancing therapeutic precision.

The experimental methodologies employed are notable for their rigor and innovation. Use of mitochondrial isolation techniques combined with real-time ROS detection enables quantitative assessment of electron transfer perturbations. Moreover, advanced imaging approaches reveal mitochondrial structural changes post-treatment, confirming the mechanistic hypothesis of ROS-induced mitochondrial damage. These comprehensive evaluations provide robust validation for the proposed therapeutic strategy.

Beyond cancer cell biology, the findings may have broader implications for diseases characterized by mitochondrial dysfunction and oxidative imbalance. Understanding how finely tuning electron transfer can modulate ROS levels opens doors for novel interventions in neurodegenerative disorders, ischemic injuries, and inflammatory conditions. Thus, this research contributes fundamentally to the expanding landscape of mitochondrial medicine, where electron transport chain components are emerging therapeutic targets.

While the promise is significant, challenges remain before clinical translation. The design of agents capable of selective complex III modulation requires precision engineering to avoid off-target effects and systemic mitochondrial toxicity. Pharmacokinetic properties, targeted delivery systems, and comprehensive safety evaluations will be essential components of future development pipelines. Nonetheless, this study provides a crucial conceptual and experimental foundation guiding these endeavors.

In summary, this groundbreaking research illuminates a novel anti-cancer mechanism centered on the modulation of electron transfer within mitochondrial complex III to induce a lethal surge in reactive oxygen species. By capitalizing on the unique bioenergetic vulnerabilities of cancer cells, this approach offers a paradigm shift in targeted therapy design, promising enhanced efficacy and reduced systemic toxicity. As the field moves forward, the strategic harnessing of mitochondrial electron transport dynamics stands poised to become a cornerstone of next-generation oncologic therapeutics.

Subject of Research: Therapeutic modulation of electron transfer in mitochondrial respiratory complex III to induce reactive oxygen species-mediated anti-cancer effects.

Article Title: Therapeutic exploration of novel reactive oxygen species-mediated anti-cancer mechanism by modulating electron transfer in respiratory complex III.

Article References:
Hagras, M.A., Jager, T. Therapeutic exploration of novel reactive oxygen species-mediated anti-cancer mechanism by modulating electron transfer in respiratory complex III. Med Oncol 42, 366 (2025). https://doi.org/10.1007/s12032-025-02938-4

Image Credits: AI Generated

At the heart of cellular bioenergetics, mitochondrial fusion and fission must strike a delicate balance for optimal function. Fusion joins mitochondria, facilitating efficient ATP production through oxidative phosphorylation (OXPHOS) and controlling reactive oxygen species (ROS) levels. Conversely, fission fragments mitochondria, a process essential for cell division, apoptosis, and metabolic reprogramming. In normal cells, these opposing forces cooperate to maintain metabolic homeostasis. However, in cancer cells, and particularly in TNBC, this equilibrium shifts decisively toward excessive fission, fueling the malignant traits of unchecked proliferation, enhanced metastatic potential, and the maintenance of cancer stem cell-like properties.

Breast cancer exhibits profound metabolic heterogeneity, a feature most prominent in the notoriously treatment-resistant TNBC. While the historical Warburg effect posited glycolysis as the dominant energy source even in oxygen-rich environments, emerging data highlight the complexity of mitochondrial metabolism’s role in cancer biology. TNBC cells leverage fatty acid oxidation (FAO) and robust mitochondrial respiration to satisfy their heightened energetic and biosynthetic demands. Enzymes like fatty acid synthase (FASN) and ATP citrate lyase elevate de novo lipogenesis, supporting membrane biosynthesis and oncogenic signaling pathways necessary for rapid tumor expansion.

Interestingly, although primary breast tumors often rely heavily on glycolysis, metastatic lesions display increased tricarboxylic acid (TCA) cycle flux and enhanced ATP generation via OXPHOS, underscoring a metabolic plasticity that allows cancer cells to adapt to varied microenvironmental stresses such as hypoxia and nutrient deprivation. This metabolic flexibility confers survival advantages and contributes to chemotherapy resistance, making mitochondrial bioenergetics a central hub for therapeutic exploration.

Mitochondrial dynamics proteins emerge as critical modulators of these metabolic shifts. The fission machinery, principally mediated by dynamin-related protein 1 (Drp1) and its receptor Fis1, is frequently upregulated in TNBC. Drp1 overexpression correlates with poor clinical prognosis and is implicated in enhancing Notch1-driven chemoresistance pathways. By promoting mitochondrial fragmentation, fission supports cell cycle progression, sustains cancer stemness, and facilitates metastatic dissemination.

On the other hand, mitochondrial fusion proteins, including mitofusins (MFN1/2) and optic atrophy 1 (OPA1), bolster mitochondrial networking, facilitating OXPHOS and balancing ROS levels. MFN2’s interaction with pyruvate kinase M2 (PKM2) attenuates glycolytic flux, imposing a metabolic check that counters oncogenic drive. Experimental inhibition of OPA1 diminishes tumor aggressiveness, emphasizing the nuanced role of fusion in moderating cancer phenotypes and suggesting potential targets to restrain malignancy.

Mitophagy, the selective autophagic clearance of damaged mitochondria, further intricately modulates the tumor milieu. The PINK1/Parkin pathway governs mitophagy, facilitating mitochondrial quality control and influencing ROS generation. In breast tumors deficient in BRCA1, mitophagy disruption elevates mitochondrial ROS, triggering NLRP3 inflammasome activation, a pro-inflammatory axis that enhances metastatic potential. Conversely, therapeutic promotion of mitophagy—using natural compounds like polyphyllin I and silibinin—can induce apoptosis in TNBC, revealing mitophagy’s dualistic role as both a survival mechanism and a vulnerability.

Therapeutic endeavors targeting mitochondrial dynamics have gained traction with preclinical studies illustrating that inhibiting mitochondrial fission can thwart cancer progression. Agents such as Mdivi-1, a Drp1 inhibitor, and the P110 peptide have demonstrated efficacy in reducing metastasis and restoring sensitivity to chemotherapeutic agents. Conversely, strategies that promote mitochondrial fusion, by enhancing MFN2 activity, repress glycolytic metabolism and impede tumor growth, providing a complementary avenue for intervention.

Moreover, modulating mitophagy has emerged as an innovative therapeutic modality. Compounds including warangalone and kaempferol induce excessive mitophagy, leading to mitochondrial dysfunction and cancer cell death, while others like cepharanthine counteract pro-survival mitophagy pathways. These findings underscore the therapeutic potential of finely tuning mitochondrial quality control processes to disrupt breast cancer’s resilient metabolic networks.

Despite promising progress, several challenges temper the clinical translation of mitochondrial-targeted therapies. Intratumoral heterogeneity means mitochondrial adaptations differ significantly among tumor subtypes and stages, necessitating precision medicine approaches. Furthermore, cancer cells’ metabolic plasticity often renders them adept at circumventing single-target treatments, underscoring the need for combinatorial regimens.

The realization of mitochondrial biomarkers as reliable clinical tools also remains in its infancy. Quantifying Drp1 expression or monitoring mitochondrial functional states through non-invasive technologies is critical to stratifying patients and gauging therapy responses. Adding another layer of complexity, advanced drug delivery systems, such as nanoparticle carriers engineered to selectively target tumor mitochondria, are being developed to enhance therapeutic efficacy and minimize off-target effects.

Looking forward, integrating multi-omics approaches to interrogate mitochondrial metabolism alongside immune modulation offers a promising research trajectory. Understanding the crosstalk between metabolic reprogramming and the tumor immune landscape may unveil synergistic combination treatments. Additionally, experimental therapies involving mitochondrial transplantation are being explored to restore mitochondrial function or alter metabolic dependencies within cancer cells, potentially opening transformative avenues in oncology.

In summation, mitochondrial dynamics stand at a crossroads of cellular metabolism, survival, and malignancy in breast cancer metastasis. Their regulation of fission, fusion, and mitophagy orchestrates complex adaptations that fuel tumor aggressiveness and therapy resistance. As our molecular understanding deepens, exploiting these mitochondrial processes represents a compelling strategy to dismantle the metabolic versatility that underpins treatment-refractory breast cancers. While hurdles remain, the future of mitochondrial-directed therapeutics in precision oncology shines brightly, promising renewed hope for patients battling aggressive breast cancer subtypes.

Subject of Research: Mitochondrial dynamics and metabolism in breast cancer metastasis

Article Title: Mitochondrial Dynamics in Breast Cancer Metastasis: From Metabolic Drivers to Therapeutic Targets

News Publication Date: 30-Mar-2025

Web References: DOI 10.14218/OnA.2025.00001

Image Credits: Bhuban Ruidas